Regeneron Pharmaceuticals (REGN) Operating Expenses (2009 - 2026)

Regeneron Pharmaceuticals' Operating Expenses history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• On a quarterly basis, Operating Expenses rose 21.56% year-over-year to $3.0 billion in Q1 2026; TTM through Mar 2026 was $11.3 billion, a 10.1% increase from a year earlier, with the FY2025 full-year figure at $10.8 billion, up 5.42% from the prior year.
• Operating Expenses declined to $3.0 billion in Q1 2026 per REGN's latest filing, from $3.0 billion in the prior quarter.
• Across five years, Operating Expenses topped out at $3.0 billion in Q4 2025 and bottomed at $1.7 billion in Q1 2022.
• The 5-year median for Operating Expenses is $2.4 billion (2025), against an average of $2.4 billion.
• Across the five-year window, Operating Expenses dropped 2.46% in 2022 and jumped 31.49% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $2.3 billion in 2022, then advanced by 8.55% to $2.5 billion in 2023, then advanced by 13.72% to $2.8 billion in 2024, then climbed by 7.34% to $3.0 billion in 2025, then fell by 1.39% to $3.0 billion in 2026.
• Per Business Quant, the three latest REGN Operating Expenses figures stand at $3.0 billion (Q1 2026), $3.0 billion (Q4 2025), and $2.7 billion (Q3 2025).